Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Hyperion DeFiHYPD +1.89%28 Debt-to-Equity is 0.16 as of Mar. 2026, which is 33% below its 10-year median of 0.24. GuruFocus rates HYPD with a GF Score™ of 28/100. The stock has 2 warning signs investors should review. Among 969 Biotechnology companies, Hyperion DeFi ranks better than 50.26% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Hyperion DeFi's Debt-to-Equity or its related term are showing as below:
HYPD'
s Debt-to-Equity Range Over the Past 10 Years
Min: -6.61 Med: 0.24 Max: 9.15
Current: 0.16
During the past 11 years, the highest Debt-to-Equity Ratio of Hyperion DeFi was 9.15. The lowest was -6.61. And the median was 0.24.
HYPD's Debt-to-Equity is ranked better than 50.26% of 969
companies
in the Biotechnology industry
Industry Median: 0.16
vs HYPD: 0.16
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Hyperion DeFi Debt-to-Equity Related Terms
Hyperion DeFi Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Hyperion DeFi's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HYPD vs PDSB, GRCE, RNXT: Debt-to-Equity Comparison
For the Biotechnology subindustry, Hyperion DeFi's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hyperion DeFi Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Hyperion DeFi's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Hyperion DeFi's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hyperion DeFi (HYPD) has a Debt-to-Equity of 0.16 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Hyperion DeFi and its competitors. This is 33% below median its historical median of 0.24. According to the industry distribution chart, Hyperion DeFi ranks #482 out of 969 companies in the Biotechnology industry, placing it in the top 49.7%.
Is Hyperion DeFi's Debt-to-Equity too high?
Hyperion DeFi's current Debt-to-Equity of 0.16 is 33% below median its 10-year median of 0.24. The Biotechnology industry median Debt-to-Equity is 0.16. Hyperion DeFi's value of 0.16 is 0% at this industry median. Based on the distribution chart, Hyperion DeFi ranks #482 out of 969 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Hyperion DeFi has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Hyperion DeFi's Debt-to-Equity compare to PDSB and GRCE?
According to the Biotechnology industry distribution chart, Hyperion DeFi ranks #482 out of 969 companies for Debt-to-Equity. This puts Hyperion DeFi in the upper half of its industry. The industry median Debt-to-Equity is 0.16. Hyperion DeFi's value of 0.16 is 0% at this benchmark. While the company's 10-year median is 0.24 vs. the industry median of 0.16, Hyperion DeFi has consistently been at the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 969 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hyperion DeFi's current Debt-to-Equity of 0.16 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Hyperion DeFi and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hyperion DeFi's current Debt-to-Equity is 0.16, which is 33% below median its own 10-year median of 0.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hyperion DeFi stock overvalued right now?
Hyperion DeFi (HYPD) has a current Debt-to-Equity of 0.16. The current Debt-to-Equity is 0.16, which is 33% below median its 10-year median of 0.24 and 0% at the Biotechnology industry median of 0.16. Hyperion DeFi's overall GF Score™ is 28/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Hyperion DeFi (HYPD), the current Debt-to-Equity is 0.16 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Hyperion DeFi Inc is a USA-based company building a long-term strategic treasury of Hyperliquid's native token, HYPE. The Company is focused on providing its shareholders with simplified access to the Hyperliquid ecosystem, one of the fastest-growing and highest-revenue-generating blockchains in the world. Shareholders benefit from a gradually compounding exposure to HYPE, both from its native staking yield and additional revenues generated from its on-chain utility. It is working to provide its shareholders with simplified exposure to the Hyperliquid ecosystem, which is believed to be among the highest-revenue-generating blockchains in the world, according to information from various blockchain data tracking sources, including Artemis Analytics and DefiLlama.
28GF Score
Get the complete analysis for HYPD
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HYPD has been successfully added to your 
